<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01878188</url>
  </required_header>
  <id_info>
    <org_study_id>BC-BLAD-01</org_study_id>
    <nct_id>NCT01878188</nct_id>
  </id_info>
  <brief_title>Pilot Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma</brief_title>
  <official_title>Phase I Study of BC-819/PEI and BCG in Patients With Superficial Transitional Cell Bladder Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Anchiano Therapeutics Israel Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Anchiano Therapeutics Israel Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      -  Safety and tolerability of three regimens of intravesically administered BC-819/PEI and&#xD;
           BCG (number of participants with AEs, discontinuations due to AEs)&#xD;
&#xD;
        -  Recurrence after treatment with BC-819/PEI and BCG&#xD;
&#xD;
        -  Approximately 38 patients with superficial transitional cell carcinoma TCC) of the&#xD;
           bladder&#xD;
&#xD;
        -  After initial evaluation and qualification, patients will be randomized to one of three&#xD;
           treatment groups, either alternating, sequential or twice weekly&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">October 2017</completion_date>
  <primary_completion_date type="Actual">October 2015</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety and tolerability of three regimens of intravesically administered BC-819/PEI and BCG by number of subjects with AEs and change from baseline for clinical safety laboratory tests</measure>
    <time_frame>3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Recurrence of bladder cancer after treatment with BC-819/PEI and BCG</measure>
    <time_frame>3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">38</enrollment>
  <condition>Transitional Cell Carcinoma of Bladder</condition>
  <arm_group>
    <arm_group_label>BC-819/PEI and BCG alternating</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 or 6 weekly treatments of BC-819/PEI alternating with 6 treatments of BCG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>BC-819/PEI and BCG Vaccine sequential</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>4 weekly treatments of BC-819/PEI followed by 6 weekly treatments of BCG</description>
  </arm_group>
  <arm_group>
    <arm_group_label>twice-weekly treatments of BC-819 and BCG</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 twice-weekly treatments of BC-819/PEI and BCG</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BC-819/PEI</intervention_name>
    <description>Intravesical instillation</description>
    <arm_group_label>BC-819/PEI and BCG Vaccine sequential</arm_group_label>
    <arm_group_label>BC-819/PEI and BCG alternating</arm_group_label>
    <arm_group_label>twice-weekly treatments of BC-819 and BCG</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BCG Vaccine</intervention_name>
    <description>intravesical instillations</description>
    <arm_group_label>BC-819/PEI and BCG Vaccine sequential</arm_group_label>
    <arm_group_label>BC-819/PEI and BCG alternating</arm_group_label>
    <arm_group_label>twice-weekly treatments of BC-819 and BCG</arm_group_label>
    <other_name>OncoTICE</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients with superficial papillary transitional cell carcinoma of the bladder for&#xD;
             whom BCG is clinically indicated. If CIS is present, diagnosis needs to be confirmed&#xD;
             by biopsy prior to the start of the study.&#xD;
&#xD;
          2. Males or females more than 18 years old&#xD;
&#xD;
          3. All papillary tumors must be resected within 8 weeks prior to the start of study&#xD;
             therapy.&#xD;
&#xD;
          4. ECOG performance status 2 or less.&#xD;
&#xD;
          5. Adequate hematologic function, as demonstrated by&#xD;
&#xD;
               1. Hemoglobin 10 g/dL or higher&#xD;
&#xD;
               2. ANC 1.5 x 109/L or higher&#xD;
&#xD;
               3. Platelets higher than 100 x 109/L&#xD;
&#xD;
          6. Adequate liver and renal function as demonstrated by&#xD;
&#xD;
               1. AST and ALT each 3.0 x ULN or less&#xD;
&#xD;
               2. Total bilirubin 1.5 x ULN or less&#xD;
&#xD;
               3. Creatinine 1.5 X ULN OR less, creatinine clearance &gt;60 mL/min&#xD;
&#xD;
          7. If fertile and sexually active, must use adequate contraception&#xD;
&#xD;
          8. Must be able to comply with protocol requirements, including attendance at required&#xD;
             clinic visits.&#xD;
&#xD;
          9. Patients must provide written informed consent.&#xD;
&#xD;
             -&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patients who are candidates for either partial or total bladder resection, unless&#xD;
             either medically contraindicated or who have refused surgery.&#xD;
&#xD;
          2. Patients with a tumor in a diverticulum, in the prostatic urethra, or covering the&#xD;
             ureteral orifice.&#xD;
&#xD;
          3. Patients who have received cytotoxic drugs, systemic corticosteroids or any&#xD;
             investigational drug for any indication within 4 weeks of the start of protocol&#xD;
             treatment.&#xD;
&#xD;
          4. Patients who have received any intravesical therapy other than surgical resection&#xD;
             within 8 weeks prior to the start of protocol treatment.&#xD;
&#xD;
          5. Patients who have received radiation therapy for bladder cancer at any time or for any&#xD;
             condition within 4 months prior to the start of protocol treatment.&#xD;
&#xD;
          6. Patients who have active infections, including urinary tract infections, whether&#xD;
             viral, bacterial or fungal and requiring therapy.&#xD;
&#xD;
          7. Patients who are receiving coumadin.&#xD;
&#xD;
          8. Patients who have had to discontinue a past course of BCG due to toxicity.&#xD;
&#xD;
          9. Patients who are having urinary tract signs or symptoms from recent urinary tract&#xD;
             procedures or manipulations, such as biopsies or catheterizations.&#xD;
&#xD;
         10. Patients who are known to be HIV positive.&#xD;
&#xD;
         11. Females who are pregnant or breast feeding.&#xD;
&#xD;
         12. Presence of any medical, psychological or social condition or situation which may, in&#xD;
             the investigator's opinion, make it difficult for the patient to tolerate study&#xD;
             medication or comply with study procedures and other requirements. This includes but&#xD;
             is not limited to active infections, poorly controlled diabetes, uncontrolled cardiac&#xD;
             arrhythmias, angina pectoris, or hypertension.&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ami Sidi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Wolfson Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Sarel Halachmi, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Bnai-Zion Medical Center, Haifa, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ilan Leibovitch, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Meir Medical Center, Kfar-Saba, Israel</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Ofer Gofrit, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Hadassah Ein Karem Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Amnon Zisman, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Assaf Harofe Medical Center</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Abraham Stein, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Carmel Hospital,Haifa</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Haim Matzkin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tel Aviv Medical Center</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Bnai Zion MC</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carmel Medical Center</name>
      <address>
        <city>Haifa</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wolfson Medical Center</name>
      <address>
        <city>Holon</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hadassah Ein Karem Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Meir MC</name>
      <address>
        <city>Kfar Saba</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tel Aviv Medical Center</name>
      <address>
        <city>Tel Aviv</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Assaf Harofe Medical Center</name>
      <address>
        <city>Zerifin</city>
        <country>Israel</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Israel</country>
  </location_countries>
  <link>
    <url>http://www.biocancell.com/</url>
    <description>Related Info</description>
  </link>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>May 29, 2013</study_first_submitted>
  <study_first_submitted_qc>June 12, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 14, 2013</study_first_posted>
  <last_update_submitted>March 8, 2019</last_update_submitted>
  <last_update_submitted_qc>March 8, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 11, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>inodiftagene vixteplasmid</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Carcinoma, Transitional Cell</mesh_term>
    <mesh_term>Urinary Bladder Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>BCG Vaccine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

